['Mirati Therapeutics', 'Bioscience', 'PartiesWe', 'HIPAA', 'Halozyme', 'BofA Securities', 'Alnylam Pharmaceuticals', 'X-Chem', 'Acuitas Therapeutics', 'Enantigen Therapeutics', 'Alnylam Pharmaceuticals', 'BioLite', 'Nocimed', 'Nocimed', 'Civitas Therapeutics', 'Pediatrix Therapeutics', 'GLP', 'the Placement Agents', 'Universal Cells', 'The Plasma Supply Agreement', 'Agility', 'the Aditx Therapeutics', 'Agility', 'Amgen', 'herein.\\\\n  ', 'GLP', 'Acorda Therapeutics', 'Spitfire Pharma', 'operations.\\\\n  &#x2022;AMX0035', 'GLP', '\\\\n    ', 'Anacor Pharmaceuticals', 'Paragon Therapeutics', 'Apogee Therapeutics', 'PropertyOur', 'SEC', 'Signature Bank', 'Medexus Pharmaceuticals', 'ContentHoldings', 'Aravive', 'Seqirus', 'Vallon Pharmaceuticals', 'GRI Bio', 'the Vinbiocare Support Agreement', 'Vinbiocare&#x2019;s', 'Janus', 'Spectrum Pharmaceutical', 'NES Therapeutic', 'GLP', 'L.P.', 'BLA', 'Riptide Bioscience', 'ModernaTX', 'Co', 'GLP', 'Papillon Therapeutics', 'BioScience', 'Astellas Pharma', 'Advance Magazine Publishers', 'Eidos Therapeutics', 'Description of Business BridgeBio Pharma', 'Resilience US', 'Navire Pharma', 'TheRas', 'Aspa Therapeutics', 'BLA', 'ASC', 'Cutanea Life Sciences', 'Leap Therapeutics', 'NanoHybrids', 'ContentsSummary', '\\\\n  &#x2022;physicians', 'the California Consumer Privacy Act', 'Toray Industries', 'Inc.\\\\n\\\\n&#160;\\\\n\\\\nViralClear\\\\nPharmaceuticals', 'the California Consumer Privacy Act', 'CalciMedica', 'Graybug Vision', 'Mana Merger Sub', 'Miromatrix Medical', 'SEC', 'Lemurian', 'GLP', 'Kolltan Pharmaceuticals', 'BioCryst Pharmaceuticals', 'Houston Pharmaceuticals', 'Reata Pharmaceuticals', 'Reata Pharmaceuticals', 'WPD\\\\nPharmaceuticals', 'Envoy Medical', 'the Business and Basis of Presentation\\\\n\\\\n&#160;\\\\n\\\\nEnvoy Medical', 'VyGen-Bio', 'Report', 'Aevitas Therapeutics', 'Pfizer', 'the Collaboration and License Agreement', 'KSQ Therapeutics', 'Axolotl Biologix', 'Overview', ': &#8226;inadequate', 'Coherent NA', 'compensation\\\\n    ', 'LetterOfCreditMember2022-12-310001654151us-gaap', 'Crystal Bioscience', 'OmniAb', 'the Dianthus Therapeutics', 'OmniAb', 'Convergent Therapeutics', 'challenges;\\\\n  &#x2022;coordination', ': &#x2022;decreased', 'Juno Therapeutics', 'eFFECTOR Therapeutics', 'Institutional Review Board', 'Anelixis Therapeutics', 'eGenesis', '\\\\n  &#x2022;whether', 'Iguana Merger Sub', '\\\\n  &#x2022;seize', '7\\\\n     &#160;Recently', 'Report', 'Aevitas Therapeutics', 'OPKO Health', 'PureForm\\\\nGlobal', 'Medytox', 'Condensed Consolidated Financial Statements', 'NoveCite', 'compensation\\\\n    ', 'Tulex Pharmaceuticals', 'Questcor Pharmaceuticals', 'SEC', 'InvaGen Pharmaceuticals', 'Sentynl Therapeutics', 'Oaktree Fund Administration', 'VYNE Therapeutics', 'Caelum Biosciences', 'InvaGen Pharmaceuticals', 'Sentynl Therapeutics', 'Oaktree Fund Administration', 'VYNE Therapeutics', 'Caelum Biosciences', 'AIRS Medical', 'Carna Biosciences', 'Bodor Laboratories', 'Brickell Subsidiary', 'Derivative InstrumentsThe Company', '\\\\n  &#x2022;physicians', 'Adare\\\\n    Pharmaceuticals', 'Integrated DNA Technologies', 'NantCell', 'Gilead Sciences', 'Crossbow Therapeutics', 'Harpoon Therapeutics', 'MPM Capital (', 'Fresenius Medical Care Holdings', 'ACA', 'RevenueThe', 'the Science and Technology Innovation Board', 'Condensed Consolidated Balance Sheets\\\\n', '\\\\n  &#x2022;diligence', 'Genentech', 'AxioMx', 'Health Technology Assessment', 'Safekeep', 'Inogen', 'L.P.', 'the Paratek Pharmaceuticals', 'Gate Neurosciences', 'InCarda Therapeutics', 'ImaginAb', 'Glaukos Corporation', 'Ivantis', 'First Citizens BancShares', 'Ending December 31,2023', 'reimbursement;\\\\n  ', 'Avalon BioVentures', 'Report', 'Aevitas Therapeutics', 'the California Institute for Regenerative Medicine (&#8220;CIRM&#8221', 'Combangio', 'ATM Offering', 'Gryphon Digital Mining', 'Regeneron Pharmaceuticals', 'L.P.', 'IndemnificationIn', 'GLP', 'Adgero Biopharmaceuticals', 'Onyx License Agreement', '50\\\\n', 'Tarsus Pharmaceuticals', 'Navire Pharma', 'Landos BioPharma', 'Lyra Therapeutics', 'QED Therapeutics', 'OrganizationLENSAR', 'Endocyte', 'Advanced Accelerator Applications USA', 'SonoThera', 'Bausch Health Companies', 'Abbott Products', 'Healthcare RegulationThe', 'Qualitative Disclosures About Market', 'Liquidia Technologies', 'the Zephyr Valves', 'LX2020', 'Condensed Consolidated Financial Statements', 'PACT Pharma', 'BofA Securities', 'the Founder Shares', 'Hercules Capital', 'Lemonaid Health', 'the Lemonaid Health', 'Liability\\\\n        ', 'Research Cooperation Technologies', 'Report', 'Aevitas Therapeutics', 'the CMCC Agreement', 'ORIC Pharmaceuticals', 'Array BioPharma', 'Report', 'Aevitas Therapeutics', 'Merger Sub', 'as\\\\nMyMD Pharmaceuticals', 'Neubase Therapeutics', 'collaboration&#8212;&#160;7,580&#160;Prepaid', 'NKGen Biotech', 'Pfizer', 'Biotech', 'Neoleukin&#8217;s', 'Alairion', 'Qualitative Disclosures About Market', 'Gemphire Therapeutics', 'Inc.', 'AvenCell Therapeutics', 'Kyverna Therapeutics', 'contracted services;\\\\n  ', 'Novartis Institutes for BioMedical Research', 'Regeneron Pharmaceuticals', 'Determination Date', 'OmniAb', 'ContentsOutstanding', 'Processa Pharmaceuticals', 'Rexahn Pharmaceuticals', 'Bank&#8217;s', 'Novartis Institutes for BioMedical Research', 'PX Instruments', 'Alexandria Real Estate Equities', 'Principal Executive Officer Pursuant', 'Cocrystal Pharma', 'Xenetic Biosciences', 'BioCardia', 'ProSomnus&#8217;s', 'L.P.', 'GLP', 'Marinus Pharmaceuticals', 'ResearchDx', 'Elion Oncology', 'the University of Maryland', 'Signature Bank', 'Progyny Rx&#8217;s PBM', 'AgonOx', 'Report', 'Aevitas Therapeutics', 'Pharmaloz Manufacturing', 'ProPhase Diagnostics', 'Novant Health', 'property;\\\\n  ', 'Takeda Pharmaceuticals USA', 'Warrants', 'Grifols Diagnostic Solutions', 'Clinigen Clinical Supplies Management', 'Protein Evolution', 'Rani Management Services', 'Organization and Nature of Business Description of Business Rani Therapeutics Holdings', 'Rani Management Services', '\\\\n    ', 'the California Consumer Privacy Act', 'Genentech', 'Roche Holdings', 'Telavant Holdings', 'Immunovant', 'Moderna Therapeutics', 'Telavant\\\\n              Holdings', 'the Hint', 'PeptiDream', 'the U.S. Securities and Exchange Commission', 'Handok', 'ActiveSite Pharmaceuticals', 'Virpax Pharmaceuticals', 'Description of Business and Basis of PreparationOrganizationSCYNEXIS', 'Hercules Capital', 'the FDA&#8217;s Quality System Regulations', 'PrognomiQ', 'name\\\\nto Shuttle Pharmaceuticals', 'Aziyo Biologics', 'SIGA Technologies', 'CMS&#8217;s', 'Zyl&#246;\\\\nTherapeutics', 'including:\\\\n  &#x2022;reduced', 'Precision Healing', 'The Catalyst Group', 'healthcare practitioners;\\\\n  &#x2022;require', 'GP Nurmenkari', 'Tebipenem HBr\\\\n    ', 'Myonexus Therapeutics', 'the &#x201c;Exchange Date&#x201d', 'Thermo Fisher Scientific', 'Lacerta Therapeutics', 'SVB', '\\\\n    ', ': &#x2022;identifying', 'Minotaur Therapeutics', 'ARIAD Pharmaceuticals', '2021&#xa0;Docklight Brands', 'Report', 'Aevitas Therapeutics', 'ImmunoFree', 'New York Blood Center', 'Signature Bank', 'Mirum Pharmaceuticals', 'NanoString Technologies', 'Globavir Biosciences', 'Nano Precision Medical', 'United&#160;Biomedical', 'Accounting PronouncementsNo', 'The Broad Institute', 'Beam', 'Planck Aerosystems', 'Viracta Therapeutics', 'NantKwest', 'Paragon Therapeutics', 'Xencor', 'Enable Injections', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'Immunogen', 'Wales', 'Anteris Bio', '\\\\n  &#x25aa;it', 'Vivos Therapeutics', 'Altesa Biosciences', 'ASC', 'OPKO Health', 'Oppenheimer &amp;\\\\nCo', 'NitricGen', 'The Nasdaq Stock Market (&#8220;Nasdaq&#8221', 'Alexion Pharmaceuticals', 'BLA', 'Zeno Management', 'Organization and BusinessOrganizationZentalis Pharmaceuticals', 'Jazz Pharmaceuticals']